Rigel Pharmaceuticals

RIGL · NASDAQ

$48.11+$1.39 (+2.98%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $46.72

About RIGL

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 172 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing therapies for patients with hematologic disorders and cancer. The company focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. The company is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Employees: 172
Headquarters: South San Francisco, California
Listed: Nov 29, 2000
Sector: Health Care
Industry: Biotechnology
Website: rigel.com

Leadership

Rigel Pharmaceuticals executives
Name	Title	Since	Age
Gregg Lapointe	—	—	66
Raul Rodriguez	—	2000	64
Dean Schorno	—	—	62
Raymond Furey	—	—	57
Lisa Rojkjaer	—	—	59
David Santos	—	—	62
Kamil Ali-Jackson	—	—	66
Mark Frohlich	—	—	63
Alison Hannah	—	—	64
Walter Moos	—	—	70
Jane Wasman	—	—	68

Revenue by product and region

Fiscal year ended Dec 31, 2025: $294.28M total revenue

By product

Product sales, net$231.98M78.8%
Contract revenues from collaborations$62.03M21.1%
Government contracts$265.00K0.1%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Rigel Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
Grifols A GRF.MC	Supplier and customer	ES	0.89
BerGenBio BGBIO.OL	Supplier and customer	NO	0.81
Bristol-Myers Squibb BMY	Supplier and customer	US	0.03
Kissei Pharmaceutical	Supplier and customer	JP	-0.25
AstraZeneca AZN.L	Supplier and customer	GB	-0.30
Eli Lilly LLY	Supplier and customer	US	-0.41
Daiichi Sankyo	Supplier and customer	JP	-0.45
AmerisourceBergen ABC	Customer	US	-0.56
McKesson MCK	Customer	US	-0.67
United States	Supplier and customer	US	—

Similar companies

Companies in the same industry as Rigel Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.